1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Lymphoedema

L-Dex U400 for lymphoedema after breast cancer treatment

Medtech innovation briefing [MIB111] Published date: 04 July 2017

  • Overview
  • Summary
  • The technology
  • Regulatory information
  • Equality considerations
  • Clinical and technical evidence
  • Specialist commentator comments
  • Specialist commentators
  • Development of this briefing
Download (PDF)

Advice

  • 2 NICE interactive flowcharts
    • Early and locally advanced breast cancer
    • Advanced breast cancer
  • Next

NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment.

What are MIBs?


  • Next